Search This Blog

Wednesday, May 13, 2026

Altimmune plans to initiate PERFORMA Phase 3 MASH trial in second half of 2026

 

Altimmune posts Q1 2026 net loss of $22.6M ($0.18 per share), with cash and investments around $535M

  • Company plans to initiate the PERFORMA Phase 3 MASH trial in the second half of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)